Oxytetracycline in the treatment of ocular rosacea: a double-blind trial.
AUTOR(ES)
Bartholomew, R S
RESUMO
Thirty-five patients with ocular rosacea were admitted to a trial of systemic oxytetracycline, 250 mg b.d. for 6 weeks. Oxytetracycline produced a significantly higher number of remissions than the placebo, 11/35. With repeated or continuous treatment 19/35 patients achieved a sustained remission for 8 months. There were no side effects. The nonspecific signs of ocular rosacea responded well to the treatment, but no permanent change in the conjunctival or corneal vascularisation occurred.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1039805Documentos Relacionados
- Naproxen in osteoarthrosis. Double-blind crossover trial.
- Penotrane in blepharitis. A double-blind controlled trial.
- Fibrinolytic enhancement by stanozolol: a double-blind trial.
- Azathioprine in active chronic iridocyclitis. A double-blind controlled trial.
- Single-dose treatment of cholera with furazolidone or tetracycline in a double-blind randomized trial.